VRTX Stock: Price, Earnings History and SEC Filings
Vertex Pharmaceuticals Incorporated (VRTX) last traded at $558.88, up 3.50% on the latest session and up 6.9% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $4.20 against an analyst estimate of $4.15, a beat of 1.2%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
VRTX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 3, 2026 | $4.20 | $4.15 | +1.20% |
| Mar 2026 | May 4, 2026 | $3.95 | $3.69 | +7.05% |
| Dec 2025 | Feb 12, 2026 | $4.65 | $4.40 | +5.68% |
| Sep 2025 | Nov 3, 2025 | $4.22 | $4.00 | +5.50% |
VRTX beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How VRTX reacts to earnings
Across its last 8 earnings releases, VRTX moved 6.1% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-03 | After close | +1.70% |
| 2026-05-04 | After close | -1.28% |
| 2026-02-12 | After close | +5.69% |
| 2025-11-03 | After close | -1.02% |
| 2025-08-04 | After close | -20.60% |
| 2025-05-05 | After close | -10.03% |
| 2025-02-10 | After close | -3.14% |
| 2024-11-04 | After close | +5.73% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
VRTX financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $12.0B | $4.0B | $3.2B | 32.9% | $15.32 |
| 2024 | $11.0B | -$536M | -$790M | -4.9% | $-2.08 |
| 2023 | $9.9B | $3.6B | $3.3B | 36.7% | $13.89 |
| 2022 | $8.9B | $3.3B | $3.9B | 37.2% | $12.82 |
| 2021 | $7.6B | $2.3B | $2.4B | 30.9% | $9.01 |
| 2020 | $6.2B | $2.7B | $3.0B | 43.7% | $10.29 |
| 2019 | $4.2B | $1.2B | $1.5B | 28.3% | $4.51 |
| 2018 | $3.0B | $2.1B | $1.2B | 68.8% | $8.09 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for VRTX
- 8-K · Oct 20, 2026Officer or director change
- 8-K · Sep 1, 2026Officer or director change
- 10-Q · Aug 4, 2026
- 8-K · Aug 3, 2026Results of operations, Financial statements and exhibits
- 8-K · Jul 7, 2026Material agreement, Regulation FD disclosure, Other events
- 8-K · May 13, 2026Officer or director change, Shareholder vote
- 10-Q · May 5, 2026
- 8-K · May 4, 2026Results of operations, Financial statements and exhibits
- 8-K · Apr 29, 2026Officer or director change
- DEF 14A · Apr 2, 2026
Insider filing activity
VRTX insiders filed 6 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
VRTX news
- Vertex Pharmaceuticals earnings: what to look for from VRTXNov 1, 2026 · finance.yahoo.com
- Vertex Pharmaceuticals (VRTX) Stock May Still Have Value Following A 190% RunNov 1, 2026 · finance.yahoo.com
- Is Vertex Pharmaceuticals (VRTX) Fully Priced Following Its Kidney Data Update?Oct 31, 2026 · finance.yahoo.com
- What Just Happened To Alnylam Stock?Oct 30, 2026 · trefis.com
- 3 large-cap stocks with solid fundamentalsOct 30, 2026 · finance.yahoo.com
- Is 50% Crash Risk For Iovance Stock Real?Oct 30, 2026 · trefis.com
- Why Did Insmed Stock Jump?Oct 30, 2026 · trefis.com
- Can Iovance Stock Fall 50%?Oct 29, 2026 · trefis.com
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated (VRTX) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in MA. Its fiscal year ends in December.